This article was originally published in Start Up
The Massachusetts-based Seedling Enterprises Inc. works with inventors who have ideas but don't know how to make them commercially viable. It selects the most promising ones, develops them, and, rather than forming a company, shops them around to potential device acquirers. Venture capitalists typically aren't interested because their targeted markets are too small. While the products may be niche, the returns, theoretically, can be pretty good--almost as good as VC returns, says co-founder Josh Tolkoff.
You may also be interested in...
Infographic timeline looks at key moments in the history of vaccine development, from the first vaccine against smallpox to the polio field trial involving 1.8 million children to the flurry of vaccines created by ‘the scientist who saved more lives than all other scientists combined.’
Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.